Generex Biotechnology Company Profile - Aug 24, 2011 by WrightReports


More Info
									Company Fundamentals\Company Profile

   A Wright Investors' Service Research Report:

   Generex Biotechnology Corporation
                                                                                        440 Wheelers Farms Road
                                                                                        Milford, CT 06461 U.S.A.

  Figures in U.S. Dollars

                                 Wright Quality Rating:LLNN                               Key Data

   Generex Biotechnology Corporation (Generex) is a development-stage company. The        Ticker:
   Company is engaged in the research, development and commercialization of drug          GNBT
   delivery systems and technologies. The Company focuses at the technology for the
   administration of formulations of large molecule drugs to the oral (buccal) cavity     2010 Sales:
   using a hand-held aerosol applicator. In October 2009, it received approval from the
   United States Food and Drug Administration (FDA) to charge to recover costs for the
   treatment use of Generex Oral-lyn in patients with Type 1 or Type 2 diabetes
   mellitus in the FDA's Treatment Investigational New Drug (IND) program that            Major Industry:
   provides for access to investigational treatments for life-threatening or otherwise    Drugs, Cosmetics & Health
   serious conditions. Using its buccal delivery technology, it has launched a line of    Care
   over-the-counter glucose and energy sprays, including Glucose RapidSpray, Crave-
   NX 7-day Diet Aid Spray, and BaBOOM! Energy Spray.                                     Sub Industry:
                       Stock Chart                                   Officers             Ethical Drug Manufacturers
                                                                  John P. Barratt         Country:
                                                                                          United States
                                                         President, Chief Executive &
                                                                 Secretary            Currency:
                                                             Mark A. Fletcher Esq.
                                                                                      U.S. Dollars

                                                              Chief Operating Officer
                                                                                          Fiscal Year Ends:
                                                                Dr. David Brusegard
                                                              Chief Financial Officer
                                                                 Stephen Fellows          Employees

To top